KRAS and neoplasm: Interestingly, this FBW7-mutant PDO was from a T4N0M1 tumor with KRAS G13D and NRAS G12D and MSS, a profile associated with lack of clinical response to EGFR-targeted therapy and anti-PD-1 immunotherapy 26, 27.